Replimune/$REPL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Replimune

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Ticker

$REPL
Sector
Primary listing

Employees

479

Replimune Metrics

BasicAdvanced
$460M
-
-$3.60
0.67
-

What the Analysts think about Replimune

Analyst ratings (Buy, Hold, Sell) for Replimune stock.

Bulls say / Bears say

The BLA priority review for RP1 plus nivolumab remains on schedule, with the FDA’s manufacturing inspections and late-cycle review now complete, supporting regulatory readiness ahead of the July 22, 2025 PDUFA date (GlobeNewswire).
Replimune has established its full commercial infrastructure—including a fully hired and trained field team, distribution channels, and key state licensing—in preparation for the anticipated RP1 launch, demonstrating strong launch-readiness (GlobeNewswire).
The global Phase 3 IGNYTE-3 trial of RP1 in combination with nivolumab is actively enrolling across over 100 planned sites, maintaining momentum for the pivotal study despite recent setbacks (GlobeNewswire).
On July 22, 2025, the FDA issued a Complete Response Letter for the RP1 Biologics License Application, indicating the application cannot be approved in its present form and highlighting that the IGNYTE trial lacked adequate evidence of effectiveness (GlobeNewswire).
Shares of Replimune fell approximately 75% following the CRL announcement, reflecting severe market reaction and heightened investor litigation risk (Barron's).
The CRL cited inadequacies in the IGNYTE trial design and patient heterogeneity, necessitating a Type A meeting with the FDA and potential redesign of confirmatory studies, likely delaying approval timelines (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.

Replimune Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Replimune Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $REPL

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs